Amneal Targets Up to 50 Launches, But Fears Diminishing Returns
Amneal has a solid roster of generics lined up for introduction in the US this year; but challenging market dynamics are forcing the company to reassess the commercial potential of these launches.
You may also be interested in...
Several generic rivals to Pfizer’s Lyrica have hit the US market following the anti-seizure and pain brand’s loss of exclusivity.
Investors have downgraded their valuation of Amneal after the US firm blamed a highly competitive local generics market for slashing its earnings forecast. To improve its competitiveness, Amneal is planning to cut 550 jobs and close two plants.
Having just sold off relatively small operations in the UK and Germany, Amneal would look for large-scale deals if it were to expand again beyond its US powerbase. The US generics and specialty brands company is also looking to expand its injectables business and is considering a move into biosimilar insulins.